These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19969602)

  • 21. [Vaccination against HPV in adults].
    Gil Á
    Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
    [No Abstract]   [Full Text] [Related]  

  • 22. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
    Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
    Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Coupé VM; Meijer CJ; Berkhof J
    J Natl Cancer Inst; 2010 Mar; 102(5):358; author reply 358. PubMed ID: 19861306
    [No Abstract]   [Full Text] [Related]  

  • 25. Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus.
    Broomall EM; Reynolds SM; Jacobson RM
    Postgrad Med; 2010 Mar; 122(2):121-9. PubMed ID: 20203463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Dec; 60(50):1705-8. PubMed ID: 22189893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papillomavirus vaccine: an updated position statement of the Society for Adolescent Health and Medicine.
    Friedman L; Bell DL; Kahn JA; Marcell AV; Middleman AB; Rosenthal SL; Zimet GD
    J Adolesc Health; 2011 Feb; 48(2):215-6. PubMed ID: 21257124
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
    de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
    Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Capri S; Ricciardi W
    Vaccine; 2010 Apr; 28(19):3379-84. PubMed ID: 20197141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus vaccine and men: what are the obstacles and challenges?
    Stupiansky NW; Alexander AB; Zimet GD
    Curr Opin Infect Dis; 2012 Feb; 25(1):86-91. PubMed ID: 22143118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
    Insinga RP; Dasbach EJ; Elbasha EH
    Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Confirming our previous comments.
    Garattini L; Casadei G
    Vaccine; 2010 Jan; 28(4):880. PubMed ID: 19925905
    [No Abstract]   [Full Text] [Related]  

  • 34. Human papillomavirus vaccine: now for boys too?
    Jenson HB; Baltimore RS
    Curr Opin Pediatr; 2011 Feb; 23(1):78-84. PubMed ID: 21157346
    [No Abstract]   [Full Text] [Related]  

  • 35. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The catch up program for human papillomavirus vaccine.
    Weisberg E
    Aust Fam Physician; 2008 Dec; 37(12):983. PubMed ID: 19149027
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-benefit analysis on the HPV vaccine in Medicaid-enrolled females of the Appalachian region of Kentucky.
    Prasad SR; Hill R
    J Ky Med Assoc; 2008 Jun; 106(6):271-6. PubMed ID: 18630037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chapter 16: HPV vaccines in immunocompromised women and men.
    Palefsky JM; Gillison ML; Strickler HD
    Vaccine; 2006 Aug; 24 Suppl 3():S3/140-6. PubMed ID: 16950001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of vaccinating boys and men against HPV in the United States.
    Elbasha EH; Dasbach EJ
    Vaccine; 2010 Oct; 28(42):6858-67. PubMed ID: 20713101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost utility analysis of human papilloma virus vaccination for females in three different age groups: a medical economics analysis.
    Wiwanitkit V
    Taiwan J Obstet Gynecol; 2011 Jun; 50(2):225-6. PubMed ID: 21791314
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.